Teaᡣ𐭩
@TeaTheDeveloper • 5,808 subscribers
Art • Humor • Trader • Writer • Programmer • Animal Lover
Shorts
Videos
Skywatch Signal Probably the the best demonstration of the 4th dimension.
Teaᡣ𐭩105,602 görüntüleme • 7 ay önce
2:32
Sensitive content
This media may contain sensitive content.
CANCER IS REAL BUSINESS Dr. Stanislaw Burzynski's unconventional cancer treatment has sparked intense debate. His Antineoplaston therapy has inspired hope in some, but the medical mainstream remains skeptical. Devotees see him as a visionary, while detractors dismiss him as a quack. The controversy raises important questions about the future of cancer treatment. Can conventional and alternative approaches find common ground? How can we balance innovation with rigor and oversight? The answers will have far-reaching implications for patients and the medical community. The debate around Dr. Stanislaw Burzynski's cancer treatment is complicated by the FDA's involvement. Critics argue that the agency's oversight has hindered Burzynski's efforts, citing instances of bureaucratic delays and stringent regulations that can slow down the approval process for new treatments. Some claim the FDA's stance is influenced by a preference for conventional therapies and pressure from the pharmaceutical industry, suggesting the agency's actions are more about protecting established interests than safeguarding patients. However, others believe the FDA is fulfilling its role of ensuring treatments meet high safety and efficacy standards. They assert that Burzynski's methods have yet to be convincingly validated and express concerns about potential risks associated with his treatment. The reality may be somewhere in the middle. While the FDA aims to protect patients, its approach can sometimes be perceived as overly strict. Finding a balance between promoting innovation and maintaining robust oversight is key to offering patients safe, effective cancer treatments while also fostering progress in medical research.
Teaᡣ𐭩125,284 görüntüleme • 2 yıl önce
Daha fazla içerik yok.